TP53 and cancer: The clonal CNVs enriched in CMS2 affected known cancer-related genes and their respective expression levels (amplifications in BRAF and PMS2; and deletions in TP53 and SMAD4, Fisher’s Test p < 0.01, Supplementary Fig. 4b).